Peptides MEX / Comparisons
Ipamorelin vs tesamorelin: mechanisms and studied populations
Ipamorelin and tesamorelin can both be linked to GH release, but their structures and research programs differ. Comparison requires separating a hormonal response in volunteers from visceral-fat changes measured in people with HIV and abdominal fat accumulation.
Updated · Sources and editorial standards
| Feature | Ipamorelin | Tesamorelin |
|---|---|---|
| Described structure[1][2] | Five-residue peptide | Modified 44-residue GRF analogue |
| Population in the cited study[3][4] | Healthy male volunteers | People with HIV and abdominal fat accumulation |
| Central endpoint[3][4] | Exposure and GH response | Visceral and liver fat |
Secretagogue pentapeptide and GRF analogue
Ipamorelin was described as a five-residue peptide acting through a GHRP-type pathway. The reference tesamorelin label describes the 44-amino-acid human GRF sequence with an N-terminal modification. This structural distinction accompanies different receptor pathways, although both can influence GH.
A biomarker versus adipose-tissue imaging
The pharmacology study of ipamorelin in healthy men measured exposure and GH release. The 2014 tesamorelin trial assessed visceral and liver fat in antiretroviral-treated people with HIV. Circulating GH and fat within a body compartment are different endpoints; one does not automatically establish the other.
Why population defines the scope
The tesamorelin trial found fat changes against placebo in its specific population. Its reference label also limits the indication to lipodystrophy in adults with HIV and states that it is not a general weight-management product. That context does not make tesamorelin and ipamorelin interchangeable for any body-composition objective.
Questions about this reference
Does more GH imply less visceral fat?
A GH response is not itself a visceral-fat measurement. That question requires body-composition endpoints and a defined population, as in the cited tesamorelin trial.
Does the EGRIFTA label verify a catalog vial?
The label documents a specific pharmaceutical formulation. It helps explain tesamorelin identity and clinical context, but does not verify another material’s composition or equivalence.
Sources and original reading
- Ipamorelin, the first selective growth hormone secretagogue
- EGRIFTA WR — tesamorelin prescribing information
- Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers
- Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial
Content updated: . How this content is prepared and checked.